NASDAQ:EDGE - Edge Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.87 +0.01 (+1.16 %)
(As of 08/21/2018 08:00 AM ET)
Previous Close$0.86
Today's Range$0.85 - $0.90
52-Week Range$0.81 - $17.77
Volume135,800 shs
Average Volume168,652 shs
Market Capitalization$26.87 million
P/E RatioN/A
Dividend YieldN/A
Edge Therapeutics logoEdge Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and seeks to commercialize hospital-based therapies for acute life-threatening neurological and other conditions. Its lead product includes EG-1962, a polymer-based microparticle used for the treatment of aneurysmal subarachnoid hemorrhage. The company is also developing EG-1964, as a prophylactic treatment for the management of chronic subdural hematoma to prevent recurrent bleeding on the surface of the brain; and EG-1965, for the prevention of post-operative atrial fibrillation. Edge Therapeutics, Inc. was founded in 2009 and is headquartered in Berkeley Heights, New Jersey.

Receive EDGE News and Ratings via Email

Sign-up to receive the latest news and ratings for EDGE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations


Debt-to-Equity RatioN/A
Current Ratio3.36
Quick Ratio3.36


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.02 per share
Price / Book0.43


EPS (Most Recent Fiscal Year)N/A
Net Income$-50,850,000.00
Net MarginsN/A
Return on Equity-92.04%
Return on Assets-62.19%


Outstanding Shares31,330,000
Market Cap$26.87 million

Edge Therapeutics (NASDAQ:EDGE) Frequently Asked Questions

What is Edge Therapeutics' stock symbol?

Edge Therapeutics trades on the NASDAQ under the ticker symbol "EDGE."

How were Edge Therapeutics' earnings last quarter?

Edge Therapeutics Inc (NASDAQ:EDGE) released its quarterly earnings results on Thursday, August, 2nd. The biotechnology company reported ($0.41) EPS for the quarter, topping analysts' consensus estimates of ($0.53) by $0.12. View Edge Therapeutics' Earnings History.

When is Edge Therapeutics' next earnings date?

Edge Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, November, 7th 2018. View Earnings Estimates for Edge Therapeutics.

What price target have analysts set for EDGE?

2 brokers have issued 12-month price objectives for Edge Therapeutics' shares. Their predictions range from $17.00 to $17.00. On average, they expect Edge Therapeutics' stock price to reach $17.00 in the next twelve months. This suggests a possible upside of 1,854.0% from the stock's current price. View Analyst Price Targets for Edge Therapeutics.

What is the consensus analysts' recommendation for Edge Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Edge Therapeutics in the last year. There are currently 1 sell rating and 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Edge Therapeutics.

Who are some of Edge Therapeutics' key competitors?

Who are Edge Therapeutics' key executives?

Edge Therapeutics' management team includes the folowing people:
  • Mr. Brian A. Leuthner, Co-Founder, CEO, Pres & Director (Age 53)
  • Dr. R. Loch MacDonald, Co-Founder, Chief Scientific Officer & Director (Age 56)
  • Dr. Herbert J. Faleck, Chief Medical Officer (Age 65)
  • Mr. Andrew Saik, Chief Financial Officer (Age 49)
  • Mr. Albert N. Marchio II, Chief Accounting & Admin. Officer (Age 66)

Has Edge Therapeutics been receiving favorable news coverage?

News coverage about EDGE stock has been trending positive on Tuesday, according to Accern Sentiment. Accern rates the sentiment of press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Edge Therapeutics earned a media and rumor sentiment score of 0.32 on Accern's scale. They also gave news stories about the biotechnology company an impact score of 44.98 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term. View Recent Headlines for Edge Therapeutics.

Who are Edge Therapeutics' major shareholders?

Edge Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Millennium Management LLC (1.63%), BlackRock Inc. (1.08%) and Raymond James Financial Services Advisors Inc. (0.51%). Company insiders that own Edge Therapeutics stock include Albert N Marchio II, Brian A Leuthner, James J Loughlin and R Loch Macdonald. View Institutional Ownership Trends for Edge Therapeutics.

Which institutional investors are selling Edge Therapeutics stock?

EDGE stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc.. Company insiders that have sold Edge Therapeutics company stock in the last year include Albert N Marchio II, Brian A Leuthner and R Loch Macdonald. View Insider Buying and Selling for Edge Therapeutics.

Which institutional investors are buying Edge Therapeutics stock?

EDGE stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC and Raymond James Financial Services Advisors Inc.. View Insider Buying and Selling for Edge Therapeutics.

How do I buy shares of Edge Therapeutics?

Shares of EDGE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Edge Therapeutics' stock price today?

One share of EDGE stock can currently be purchased for approximately $0.87.

How big of a company is Edge Therapeutics?

Edge Therapeutics has a market capitalization of $26.87 million. Edge Therapeutics employs 38 workers across the globe.

How can I contact Edge Therapeutics?

Edge Therapeutics' mailing address is 300 Connell Drive Suite 4000, Berkeley Heights NJ, 07922. The biotechnology company can be reached via phone at 800-208-3343 or via email at [email protected]

MarketBeat Community Rating for Edge Therapeutics (NASDAQ EDGE)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  124 (Vote Outperform)
Underperform Votes:  130 (Vote Underperform)
Total Votes:  254
MarketBeat's community ratings are surveys of what our community members think about Edge Therapeutics and other stocks. Vote "Outperform" if you believe EDGE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EDGE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/21/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel